The software assists radiologists during reviews of CT colonography (CTC, a.k.a. virtual colonoscopy) images by automatically highlighting potential colorectal polyps, which are possible precursors to colorectal cancer.
Medicsight PLC and Ziosoft Inc., have announced the integration of Medicsight’s ColonCAD API software and Ziosoft’s Ziostation. Ziosoft, based in Redwood City, Calif., will distribute the technologies in the United States under the terms of the deal.
The FDA approved ColonCAD API for clinical use in May. The software assists radiologists during reviews of CT colonography (CTC, a.k.a. virtual colonoscopy) images by automatically highlighting potential colorectal polyps, which are possible precursors to colorectal cancer. The FDA’s green light came after a clinical trial involving 15 radiologist readers who each reviewed 112 patient CT colonography cases. When assisted by ColonCAD, radiologists’ accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading, Medicsight officials said.
“The partnership between Ziosoft and Medicsight should make a compelling match for CT colonography interpretation,” said Perry J. Pickhardt, professor of Radiology at the University of Wisconsin, one of the first U.S. sites slated to use the combined Medicsight and Ziosoft technologies. “CTC will definitely benefit from the pairing of these companies which are two recognized leaders in the advanced visualization field.”
Ziosoft holds numerous clearances for applications for its supercomputing visualization and functional analytics technology. Medicsight and Ziosoft have been partnering in Europe prior to the U.S. clearance of ColonCAD software.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).